Fate Therapeutics, Inc. Common Stock FATE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T14:57:22.168Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:57:11.769511317Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T14:57:20.524072+00:00
Fate Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 4.87 | 690.2% | 257.9% | |||
| 30Δ | 4.57 | 728.0% | 244.5% | |||
| 35Δ | 4.27 | 765.8% | 231.2% | |||
| 40Δ | 3.96 | 797.3% | 216.0% | 1.57 | 499.0% | 26.5% |
| 45Δ | 3.49 | 769.1% | 183.0% | 1.79 | 486.8% | 24.2% |
| 50Δ | 3.03 | 740.8% | 150.0% | 2.02 | 474.5% | 21.8% |
| 55Δ | 2.56 | 712.6% | 117.1% | 2.24 | 462.3% | 19.5% |
| 60Δ | 2.10 | 684.4% | 84.1% | 2.46 | 450.1% | 17.1% |
| 65Δ | 1.63 | 656.2% | 51.1% | 2.68 | 437.9% | 14.7% |
| 70Δ | 1.36 | 611.8% | 34.2% | 2.90 | 425.6% | 12.4% |
| 75Δ | 1.18 | 561.0% | 23.5% | 3.12 | 413.4% | 10.0% |
| 80Δ | 0.99 | 519.0% | 13.3% | 3.35 | 401.2% | 7.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.87
- IV
- 690.2%
- B/E move
- 257.9%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 4.57
- IV
- 728.0%
- B/E move
- 244.5%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 4.27
- IV
- 765.8%
- B/E move
- 231.2%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.96
- IV
- 797.3%
- B/E move
- 216.0%
- Pseudo strike
- 1.57
- IV
- 499.0%
- B/E move
- 26.5%
45Δ
- Pseudo strike
- 3.49
- IV
- 769.1%
- B/E move
- 183.0%
- Pseudo strike
- 1.79
- IV
- 486.8%
- B/E move
- 24.2%
50Δ
- Pseudo strike
- 3.03
- IV
- 740.8%
- B/E move
- 150.0%
- Pseudo strike
- 2.02
- IV
- 474.5%
- B/E move
- 21.8%
55Δ
- Pseudo strike
- 2.56
- IV
- 712.6%
- B/E move
- 117.1%
- Pseudo strike
- 2.24
- IV
- 462.3%
- B/E move
- 19.5%
60Δ
- Pseudo strike
- 2.10
- IV
- 684.4%
- B/E move
- 84.1%
- Pseudo strike
- 2.46
- IV
- 450.1%
- B/E move
- 17.1%
65Δ
- Pseudo strike
- 1.63
- IV
- 656.2%
- B/E move
- 51.1%
- Pseudo strike
- 2.68
- IV
- 437.9%
- B/E move
- 14.7%
70Δ
- Pseudo strike
- 1.36
- IV
- 611.8%
- B/E move
- 34.2%
- Pseudo strike
- 2.90
- IV
- 425.6%
- B/E move
- 12.4%
75Δ
- Pseudo strike
- 1.18
- IV
- 561.0%
- B/E move
- 23.5%
- Pseudo strike
- 3.12
- IV
- 413.4%
- B/E move
- 10.0%
80Δ
- Pseudo strike
- 0.99
- IV
- 519.0%
- B/E move
- 13.3%
- Pseudo strike
- 3.35
- IV
- 401.2%
- B/E move
- 7.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 175.44% | |
| 147.21% | |
| 268.27% | |
| 150.98% | |
| 195.31% | |
| 194.39% | |
| 195.16% | |
| 234.10% | |
| 214.42% | |
| 181.98% | |
| 191.33% | |
| 176.65% | |
| 203.84% | |
| 162.94% | |
| 181.89% | |
| 199.82% | |
| 182.87% | |
| 180.27% |
Biotechnology
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in…
More →FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in…
More →FLNA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach,…
More →FTRE
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
More →FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas…
More →GALT
Description unavailable
More →